208 results on '"Brehler, Randolf"'
Search Results
2. Allergen-specific immunotherapy for mold allergies
3. Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet
4. Avoidance measures for mite allergy—an update
5. Clinic and diagnostics of house dust mite allergy
6. Allergen characteristics, quality, major allergen content and galenics for mite allergen-specific immunotherapy preparations
7. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
8. Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study
9. White paper on peanut allergy – part 1: Epidemiology, burden of disease, health economic aspects
10. Immunologically relevant aspects of the new COVID-19 vaccines—an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper
11. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
12. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA)
13. Healthcare provision for insect venom allergy patients during the COVID-19 pandemic
14. ARIA guideline 2019: treatment of allergic rhinitis in the German health system
15. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.
16. Correction to “ARIA guideline 2019: treatment of allergic rhinitis in the German health system”
17. Aluminium (Al) speciation in serum and urine after subcutaneous venom immunotherapy with Al as adjuvant
18. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG)
19. Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations
20. Evolution of subcutaneous allergen immunotherapy (part 1): from first developments to mechanism-driven therapy concepts
21. Allergen-specific immunotherapy with storage mites: A neglected indication
22. S2k‐Leitlinie Diagnostik, Prävention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczema.
23. S2k guideline diagnosis, prevention, and therapy of hand eczema.
24. Insects and arachnids as elicitors of toxic and allergic reactions in Germany
25. Correction to: Guideline for the diagnosis of drug hypersensitivity reactions
26. COVID-19-Impfungen von Patienten mit Allergien und Typ2-entzündlichen Erkrankungen bei gleichzeitiger Antikörpertherapie (Biologika)
27. Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe
28. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence
29. Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe
30. Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany
31. Schwere allergische Reaktionen nach COVID-19-Impfung mit dem Impfstoff von Pfizer/BioNTech in Großbritannien und USA
32. S3 Guideline Urticaria. Part 2: Treatment of urticaria – German‐language adaptation of the international S3 guideline.
33. S3‐Leitlinie Urtikaria. Teil 2: Therapie der Urtikaria – deutschsprachige Adaption der internationalen S3‐Leitlinie.
34. S3‐Leitlinie Urtikaria. Teil 1: Klassifikation und Diagnostik der Urtikaria – deutschsprachige Adaptation der internationalen S3‐Leitlinie.
35. S3 Guideline Urticaria. Part 1: Classification and diagnosis of urticaria – German‐language adaptation of the international S3 Guideline.
36. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM)
37. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c
38. Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity.
39. The European Curriculum for Additional Qualification Allergology A Position Paper by Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) in cooperation with European Academy for Allergology and Clinical Immunology (EAACI) and Allergology Section of European Union of Medical Specialists (UEMS)
40. Allergy – current insights into prevention and diagnostic workup of immediate-type allergy and treatment of allergic rhinoconjunctivitis
41. Allergologie – Aktuelles zur Prävention und Diagnostik von Soforttyp-Allergien und zur Therapie der allergischen Rhinokonjunktivitis
42. Contact sensitization to essential oils: IVDK data of the years 2010–2019.
43. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma
44. German S1 guideline: Contact dermatitis.
45. S1‐Leitlinie Kontaktekzem.
46. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic:Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)
47. Latex allergy
48. Modulation of basophil activity: A novel function of the neuropeptide α-melanocyte–stimulating hormone
49. Druckurtikaria – Dapson auf dem Weg zur First-Line-Therapie?
50. Delayed pressure urticaria – Dapsone heading for first-line therapy?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.